A Phase 2/3 interventional study of Duloxetine and Escitalopram in Fibromyalgia, sponsored by Shaheed Zulfiqar Ali Bhutto Medical University. Completed at 1 site in Pakistan. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-02-27.
Sponsored by Shaheed Zulfiqar Ali Bhutto Medical University · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Fibromyalgia with a site in Pakistan — 4 open to participants now, 5 under way, none of them phase 3. Fibromyalgia · Pakistan.
Among the 10 studies in Fibromyalgia with a site in Pakistan, this one is the only one that started in 2018, is the only one in phase 2/3, and was the 1st registered.
1,244 studies on the registry are indexed under Fibromyalgia; 255 are open to participants now.
Browse Fibromyalgia studies →4 of the 10 studies in Fibromyalgia with a site in Pakistan are open now. Recruiting first, the newest first:
Shaikh Zayed Hospital, Lahore · Sites in Pakistan
Ages 18–65
Riphah International University · Sites in Pakistan
Ages 20–39 · Women only
Riphah International University · Sites in Pakistan
Ages 30–65
University of Karachi · Sites in Pakistan
Ages 60–80
A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →
Of the 160 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 60 across 938 interventional studies indexed under Fibromyalgia.
Median enrollment 54 across the 9 interventional studies, 90 across the 1 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 10 has an industry lead sponsor. The 7 most frequent:
Shaheed Zulfiqar Ali Bhutto Medical University is the lead sponsor of 39 studies on the registry; 6 are open to participants now.
Shaheed Zulfiqar Ali Bhutto Medical University has 1 study filed under Fibromyalgia — fewer than ten, so there is no comparison to draw.
1 of the studies in Fibromyalgia with a site in Pakistan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07585045Shaikh Zayed Hospital, LahoreEffectiveness of Oral Magnesium Supplementation in Fibromyalgia Patients Not Responding to Standard Treatment | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Fibromyalgia with a site in Pakistan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Duloxetine is FDA approved as pharmacological treatment for Fibromyalgia. The use of SSRIs has been endorsed by the 2013 Canadian guidelines. The data available for Escitalopram as a treatment modality for Fibromyalgia is limited, however small trials have demonstrated its efficacy. No head to head comparisons between escitalopram and duloxetine have been undertaken. We aim to conduct a single blind, randomized control trial to assess the comparative efficacy of duloxetine vs escitalopram in drug naive patients with newly diagnosed Fibromyalgia.
180 drug naive patients with newly diagnosed fibromyalga according to the modified ACR 2016 criteria shall be enrolled by consecutive sampling after taking written informed consent. Baseline severity of fibromyalgia shall be assessed via the Revised Fibromyalgia Impact Questionnaire (FIQ-R). They shall be randomized via cluster randomization into two groups. The first group shall receive Duloxetine 30mg, will be increased to 60mg after one week. The second group shall receive Escitalopram 10mg to be increased to 20mg after one week. Patients shall be followed at 0,2,4,8 and 12 weeks. At each visit, any subjective change in symptoms shall be noted and the FIQ-R shall be re administered. At the end of the trial, the overall change in the FIQ-R from baseline shall be assessed and the difference between both groups will be analyzed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Duloxetine 30mg once daily to be started for 1 week. Dose will then be titrated to 60mg once daily and the patients followed for a total of 12 weeks.
Drug: Duloxetine
Escitalopram 10mg once daily to be started for 1 week. Dose will then be titrated to 20mg once daily and the patients followed for a total of 12 weeks.
Drug: Escitalopram
Duloxetine 30mg PO once daily for 1 week followed by an increase to 60mg PO once daily
Also known as: DUPREX
Escitalopram 10mg PO once daily for 1 week followed by an increase to 20mg PO once daily
Also known as: EXAPRO
Reduction in FIQ-R (Revised Fibromyalgia Impact Questionnaire) from baseline
Percentage decrease in FIQ-R from baseline
Time frame: 4,8 and 12 weeks
Plan to share: No
Ran from Apr 2018 to primary completion in Feb 2020, 22 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Escitalopram
Shaheed Zulfiqar Ali Bhutto Medical University